Charles Cashion - Conatus Pharmaceuticals Insider

CNAT -- USA Stock  

USD 4.72  0.56  13.46%

Mr. Charles J. Cashion is Chief Financial Officer, Senior Vice President of Finance, Secretary of Conatus Pharmaceuticals Inc., since July 2005. From 2001 to 2005, he was Chief Financial Officer at Idun. He has held several senior level management positions in both private and public healthcare companies with responsibilities for securing and executing various types of financings including initial public offerings, secondary offerings, corporate partnerships, and debt. He has also been involved with the strategic planning, acquisition and integration of several technology companies. He joined Idun Pharmaceuticals in 2001 as Executive Vice President, Chief Financial Officer and Secretary. Previously, he held the position of Senior Vice President and Chief Financial Officer of Quidel Corporationrationration, a publiclyheld medical diagnostics company. For the prior nine years, he was Senior Vice President, Finance, and Chief Financial Officer of The Immune Response Corporationrationration, a publiclyheld biopharmaceutical company. During the period from 1980 to 1989, he was Executive Vice President and Chief Financial Officer of Smith Laboratories, Inc., a publiclyheld pharmaceutical company and during 1987 through 1989 was also President and Chief Executive Officer of Sutter Corporationrationration, an orthopedic products subsidiary of Smith Laboratories. He also held positions at Baxter International, Inc. and Motorola, Inc. He serves on the boards of directors of NovaBay Pharmaceuticals, Inc., Ridge Diagnostics, Inc., La Jolla Institute for Allergy Immunology, and iDiverse, Inc
Age: 64  President Since 2005  MBA    
Cashion holds an M.B.A. and B.S. in Accounting from Northern Illinois University.

Management Efficiency

The company has return on total asset (ROA) of (13.62) % which means that it has lost $13.62 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (65.88) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 13.53 M in liabilities with Debt to Equity (D/E) ratio of 67.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Conatus Pharmaceuticals has Current Ratio of 2.3 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 11 records


David MozleyEndocyte
David JohnsonDynavax Technologies Corporatio
Bradford MiddlekauffEdge Therapeutics
Katherine ParkerEndocyte
Robert JanssenDynavax Technologies Corporatio
Erik CheliusEndocyte
Michael OstrachDynavax Technologies Corporatio
Michael BrinkleyEndocyte
Theodore AshburnDicerna Pharmaceuticals
Alyssa WyantEdge Therapeutics
Kevin LaliberteDova Pharmaceuticals

Entity Summary

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. The company was founded in 2005 and is headquartered in San Diego, California. Conatus Pharmaceuticals operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 33 people.Conatus Pharmaceuticals (CNAT) is traded on BATS Exchange in USA. It is located in CALIFORNIA U.S.A and employs 33 people. Conatus Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Conatus Pharmaceuticals Leadership Team

Edward Smith, Senior Vice President - Regulatory Affairs and Quality Assurance
Michelle Vandertie, Acting Principal Accounting Officer
Dan Kisner, Additional Independent Director
James Scopa, Independent Director
Steven Mento, Co-Founder, CEO and President and Director
Daniel Kisner, Additional Independent Director
Preston Klassen, Additional Independent Director
David Hale, Independent Chairman of the Board
Harold Wart, Independent Director
William LaRue, Additional Independent Director
Alfred Spada, Co-Founder, Chief Scientific Officer and Executive VP of RandD
Charles Cashion, CFO, Senior Vice President of Finance, Secretary
Daniel Ripley, Senior Vice President - Business Development, Program and Alliance Management
Keith Marshall, CFO, Principal Financial Officer, COO, Executive Vice President
Louis Lacasse, Independent Director
Shahzad Malik, Independent Director
David Hagerty, Executive Vice President Clinical Development

Stock Performance Indicators

Current Sentiment - CNAT

Conatus Pharmaceuticals Investor Sentiment

Most of Macroaxis users are currently bullish on Conatus Pharmaceuticals. What is your opinion about investing in Conatus Pharmaceuticals? Are you bullish or bearish?
98% Bullish
2% Bearish

Conatus Pharmaceuticals Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Conatus Pharmaceuticals and China Cord Blood. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.